Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Leukemia

  Free Subscription


Articles published in Eur J Haematol

Retrieve available abstracts of 61 articles:
HTML format
Text format



Single Articles


    February 2019
  1. CAPODANNO I, Tamagnini E, Alfieri P, Codeluppi K, et al
    Home Care of Acute Leukemia Patients: from Active Therapy to End-of-Life and Palliative Care. The Three-year Experience of a Single Centre.
    Eur J Haematol. 2019 Feb 22. doi: 10.1111/ejh.13224.
    PubMed     Text format     Abstract available


  2. ISHITSUKA K, Yurimoto S, Tsuji Y, Iwabuchi M, et al
    Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma.
    Eur J Haematol. 2019 Feb 10. doi: 10.1111/ejh.13220.
    PubMed     Text format     Abstract available


    December 2018
  3. GRIFFIN JD, Yang H, Song Y, Kinrich D, et al
    Treatment Patterns and Healthcare Resource Utilization in Patients with FLT3-Mutated and Wild Type Acute Myeloid Leukemia: A Medical Chart Study.
    Eur J Haematol. 2018 Dec 22. doi: 10.1111/ejh.13205.
    PubMed     Text format     Abstract available


  4. BALSAT M, Etienne M, Elhamri M, Hayette S, et al
    Successful pregnancies in patients with BCR-ABL-positive leukemias treated with interferon-alpha therapy during the tyrosine kinase inhibitors era.
    Eur J Haematol. 2018;101:774-780.
    PubMed     Text format     Abstract available


  5. WEHMEYER J, Zaiss M, Losem C, Schmitz S, et al
    Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).
    Eur J Haematol. 2018;101:766-773.
    PubMed     Text format     Abstract available


    October 2018
  6. BERTOLI S, Paubelle E, Berard E, Saland E, et al
    Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels and their functional as well as prognostic roles in acute myeloid leukemia.
    Eur J Haematol. 2018 Oct 16. doi: 10.1111/ejh.13183.
    PubMed     Text format     Abstract available


  7. AYPAR U, Smoley SA, Pitel BA, Pearce KE, et al
    Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia.
    Eur J Haematol. 2018 Oct 1. doi: 10.1111/ejh.13179.
    PubMed     Text format     Abstract available


  8. ZAWITKOWSKA J, Lejman M, Zaucha-Prazmo A, Drabko K, et al
    Clinical characteristics and analysis of treatment result in children with Ph-positive acute lymphoblastic leukaemia in Poland between 2005 and 2017.
    Eur J Haematol. 2018;101:542-548.
    PubMed     Text format     Abstract available


    September 2018
  9. BARBA P, Morgades M, Montesinos P, Gil C, et al
    Increased Survival due to Lower Toxicity for High Risk T-cell Acute Lymphoblastic Leukemia Patients in 2 consecutive Pediatric-Inspired PETHEMA Trials.
    Eur J Haematol. 2018 Sep 29. doi: 10.1111/ejh.13178.
    PubMed     Text format     Abstract available


  10. KAYSER S, Levis MJ
    Clinical Implications of Molecular Markers in Acute Myeloid Leukemia.
    Eur J Haematol. 2018 Sep 10. doi: 10.1111/ejh.13172.
    PubMed     Text format     Abstract available


  11. GAYOSO J, Balsalobre P, Kwon M, Herrera P, et al
    Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes.
    Eur J Haematol. 2018;101:332-339.
    PubMed     Text format     Abstract available


  12. KRIEGSMANN K, Loffler H, Eckstein V, Schulz R, et al
    CD7 is expressed on a subset of normal CD34-positive myeloid precursors.
    Eur J Haematol. 2018;101:318-325.
    PubMed     Text format     Abstract available


  13. WANG WJ, Zheng CF, Liu Z, Tan YH, et al
    Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression.
    Eur J Haematol. 2018;101:291-296.
    PubMed     Text format     Abstract available


    August 2018
  14. CALITRI C, Ruberto E, Castagnola E
    Antibiotic prophylaxis in neutropenic children with acute leukemia: do the presently available data really support this practice?
    Eur J Haematol. 2018 Aug 14. doi: 10.1111/ejh.13162.
    PubMed     Text format     Abstract available


  15. LAM TS, van de Meent M, Marijt EWA, Falkenburg JHF, et al
    Immune surveillance by autoreactive CD4 positive helper T-cells is a common phenomenon in patients with acute myeloid leukemia.
    Eur J Haematol. 2018 Aug 4. doi: 10.1111/ejh.13157.
    PubMed     Text format     Abstract available


    July 2018
  16. HOEKS M, van der Pol M, Middelburg R, Evers D, et al
    Bone marrow iron score as an indicator for secondary iron overload in acute myeloid leukemia patients.
    Eur J Haematol. 2018 Jul 17. doi: 10.1111/ejh.13145.
    PubMed     Text format     Abstract available


  17. BOUVIER A, Ribourtout B, Francois S, Orvain C, et al
    Donor cell-derived acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplantation.
    Eur J Haematol. 2018 Jul 14. doi: 10.1111/ejh.13143.
    PubMed     Text format     Abstract available


  18. ZACHARAKI D, Ghazanfari R, Li H, Lim HC, et al
    Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
    Eur J Haematol. 2018;101:57-67.
    PubMed     Text format     Abstract available


  19. ARCIONI F, Roncadori A, Di Battista V, Tura S, et al
    Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
    Eur J Haematol. 2018;101:78-85.
    PubMed     Text format     Abstract available


    June 2018
  20. JOFFE E, Goldschmidt N, Bairey O, Fineman R, et al
    Outcomes of Second-Line Treatment After Fludarabine Cyclophosphamide and Rituximab in Patients with Chronic Lymphocytic Leukemia Outside Clinical Trials.
    Eur J Haematol. 2018 Jun 27. doi: 10.1111/ejh.13129.
    PubMed     Text format     Abstract available


  21. LATAGLIATA R, Breccia M, Carmosino I, Cesini L, et al
    Clinical Results According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: the Younger, the Later, the Worse?
    Eur J Haematol. 2018 Jun 13. doi: 10.1111/ejh.13110.
    PubMed     Text format     Abstract available


  22. CLAERHOUT H, Van Aelst S, Melis C, Tousseyn T, et al
    Clinicopathological characteristics of de novo and secondary myeloid sarcoma: A monocentric retrospective study.
    Eur J Haematol. 2018;100:603-612.
    PubMed     Text format     Abstract available


    May 2018
  23. BALL S, Vutthikraivit W, Maiti A, Short NJ, et al
    Infection with Ibrutinib in patients with Chronic Lymphocytic Leukemia (CLL): How strong is the association?
    Eur J Haematol. 2018 May 23. doi: 10.1111/ejh.13098.
    PubMed     Text format     Abstract available


  24. REISER M, Dorfel S, Hensel M, Hoesl M, et al
    Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice.
    Eur J Haematol. 2018;100:455-464.
    PubMed     Text format     Abstract available


  25. KURT H, Jorgensen JL, Amin HM, Patel KP, et al
    Chronic lymphoproliferative disorder of NK-cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools.
    Eur J Haematol. 2018;100:444-454.
    PubMed     Text format     Abstract available


    April 2018
  26. OTA S, Matsukawa T, Yamamoto S, Shinichi I, et al
    Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Eur J Haematol. 2018 Apr 16. doi: 10.1111/ejh.13081.
    PubMed     Text format     Abstract available


  27. TIEN FM, Hou HA, Tsai CH, Tang JL, et al
    Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients.
    Eur J Haematol. 2018 Apr 6. doi: 10.1111/ejh.13073.
    PubMed     Text format     Abstract available


  28. GEELEN IGP, Thielen N, Janssen JJWM, Hoogendoorn M, et al
    Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe.
    Eur J Haematol. 2018;100:367-371.
    PubMed     Text format     Abstract available


    March 2018
  29. PALMA M, Hansson L, Mulder TA, Adamson L, et al
    Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients.
    Eur J Haematol. 2018 Mar 23. doi: 10.1111/ejh.13065.
    PubMed     Text format     Abstract available


  30. ULLMARK T, Montano G, Gullberg U
    DNA and RNA binding by the Wilms' tumour gene 1 (WT1) protein +KTS and -KTS isoforms-From initial observations to recent global genomic analyses.
    Eur J Haematol. 2018;100:229-240.
    PubMed     Text format     Abstract available


  31. ALJASEM HA, Messner HA, Lipton JH, Kim DDH, et al
    Outcome following second allogeneic hematopoietic cell transplantation: A single-center experience.
    Eur J Haematol. 2018;100:308-314.
    PubMed     Text format     Abstract available


  32. CASADO LF, Hernandez JA, Jarque I, Echave M, et al
    Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia.
    Eur J Haematol. 2018;100:264-272.
    PubMed     Text format     Abstract available


    February 2018
  33. ROBAK T, Blonski J, Skotnicki AB, Piotrowska M, et al
    Rituximab, cladribine and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial.
    Eur J Haematol. 2018 Feb 10. doi: 10.1111/ejh.13042.
    PubMed     Text format     Abstract available


  34. KHALIL MMI, Lipton JH, Atenafu EG, Gupta V, et al
    Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia.
    Eur J Haematol. 2018;100:198-205.
    PubMed     Text format     Abstract available


    January 2018
  35. BURILLO-SANZ S, Morales-Camacho RM, Caballero-Velazquez T, Carrillo E, et al
    MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.
    Eur J Haematol. 2018 Jan 31. doi: 10.1111/ejh.13037.
    PubMed     Text format     Abstract available


  36. MURAI K, Yamaguchi K, Ito S, Miyagishima T, et al
    Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patients.
    Eur J Haematol. 2018;100:27-35.
    PubMed     Text format     Abstract available


    December 2017
  37. CUI W, Wang J, Nie RM, Zhao LL, et al
    Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
    Eur J Haematol. 2017 Dec 20. doi: 10.1111/ejh.13018.
    PubMed     Text format     Abstract available


  38. JAMROZIAK K, Szymczyk A, Hus M, Wojciechowska M, et al
    Hodgkin's variant of Richter's transformation during ibrutinib therapy in a series of CLL patients; the Polish Adult Leukemia Group report (PALG).
    Eur J Haematol. 2017 Dec 15. doi: 10.1111/ejh.13016.
    PubMed     Text format     Abstract available


  39. GONG X, Lin D, Wang H, Wang Y, et al
    Flow Cytometric Analysis of Cerebrospinal Fluid in Adult Patients with Acute Lymphoblastic Leukemia during Follow-Up.
    Eur J Haematol. 2017 Dec 14. doi: 10.1111/ejh.13011.
    PubMed     Text format     Abstract available


    November 2017
  40. SCHILLER J, Klein S, Engels M, Buttner R, et al
    A Cryptosporidium infection in a patient with relapsed T lymphoblastic lymphoma undergoing allogeneic stem cell transplantation.
    Eur J Haematol. 2017 Nov 15. doi: 10.1111/ejh.12998.
    PubMed     Text format     Abstract available


  41. LENGFELDER E, Gorlich D, Nowak D, Spiekermann K, et al
    Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines.
    Eur J Haematol. 2017 Nov 7. doi: 10.1111/ejh.12994.
    PubMed     Text format     Abstract available


  42. COMBARIZA JF, Toro LF, Orozco JJ, Arango M, et al
    Cost-effectiveness analysis of interventions for prevention of invasive aspergillosis among leukemia patients during hospital construction activities.
    Eur J Haematol. 2017 Nov 6. doi: 10.1111/ejh.12991.
    PubMed     Text format     Abstract available


    October 2017
  43. GONSALVES WI, Buadi FK, Kumar SK
    Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14).
    Eur J Haematol. 2017 Oct 24. doi: 10.1111/ejh.12986.
    PubMed     Text format     Abstract available


  44. DUPLOYEZ N, Abou Chahla W, Lejeune S, Marceau-Renaut A, et al
    Detection of a new heterozygous germline ETV6 mutation in a case with hyperdiploid acute lymphoblastic leukemia (ALL).
    Eur J Haematol. 2017 Oct 16. doi: 10.1111/ejh.12981.
    PubMed     Text format     Abstract available


  45. TULSTRUP M, Frandsen TL, Abrahamsson J, Lund B, et al
    Individualized 6-mercaptopurine increments in consolidation treatment of childhood acute lymphoblastic leukemia: a NOPHO randomized controlled trial.
    Eur J Haematol. 2017 Oct 6. doi: 10.1111/ejh.12979.
    PubMed     Text format     Abstract available


    September 2017
  46. KAYSER S, Feszler M, Krzykalla J, Schick M, et al
    Clinical Impact of KMT2C and SPRY4 Expression Levels in Intensively Treated Younger Adult Acute Myeloid Leukemia Patients.
    Eur J Haematol. 2017 Sep 22. doi: 10.1111/ejh.12972.
    PubMed     Text format     Abstract available


  47. SZARZYNSKA-ZAWADZKA B, Kosmalska M, Sedek L, Sonsala A, et al
    Cost-effective screening of DNMT3A coding sequence identifies somatic mutation in pediatric T-cell acute lymphoblastic leukemia.
    Eur J Haematol. 2017 Sep 14. doi: 10.1111/ejh.12964.
    PubMed     Text format     Abstract available


    August 2017
  48. ISHIKAWA C, Senba M, Hashimoto T, Imaizumi A, et al
    Expression and significance of Pim-3 kinase in adult T-cell leukemia.
    Eur J Haematol. 2017 Aug 19. doi: 10.1111/ejh.12940.
    PubMed     Text format     Abstract available


  49. PAPROCKA M, Bielawska-Pohl A, Rossowska J, Krawczenko A, et al
    MRP1 protein expression in leukemic stem cells as a negative prognostic marker in acute myeloid leukemia patients.
    Eur J Haematol. 2017 Aug 14. doi: 10.1111/ejh.12938.
    PubMed     Text format     Abstract available


  50. WANG W, Bochtler T, Wuchter P, Manta L, et al
    Mesenchymal stromal cells contribute to quiescence of therapy resistant leukemic cells in acute myeloid leukemia.
    Eur J Haematol. 2017 Aug 11. doi: 10.1111/ejh.12934.
    PubMed     Text format     Abstract available


    July 2017
  51. GEELEN IGP, Thielen N, Janssen JJWM, Levin MD, et al
    Influence of WHO versus ELN advanced phase chronic myeloid leukemia definitions on overall survival.
    Eur J Haematol. 2017 Jul 18. doi: 10.1111/ejh.12928.
    PubMed     Text format     Abstract available


    June 2017
  52. D'ARENA G, Vitale C, Perbellini O, Coscia M, et al
    Prognostic relevance of oxidative stress measurement In chronic lymphocytic leukemia.
    Eur J Haematol. 2017 Jun 24. doi: 10.1111/ejh.12918.
    PubMed     Text format     Abstract available


  53. NASILOWSKA-ADAMSKA B, Warzocha K, Solarska I, Borg K, et al
    BCRP mRNA and FLT3-ITD are independent poor risk factors in adult patients with acute myeloid leukemia and intermediate or normal karyotype.
    Eur J Haematol. 2017 Jun 15. doi: 10.1111/ejh.12913.
    PubMed     Text format     Abstract available


  54. PELLO OM, Innes AJ, Bradshaw A, Finn SA, et al
    BKV-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation.
    Eur J Haematol. 2017;98:632-634.
    PubMed     Text format     Abstract available


    May 2017
  55. GLAVEY S, Quinn J, McCloy M, Sargent J, et al
    Emergence of Bruton's Tyrosine Kinase-negative Hodgkin Lymphoma During Ibrutinib Treatment of Chronic Lymphocytic Leukaemia.
    Eur J Haematol. 2017 May 31. doi: 10.1111/ejh.12911.
    PubMed     Text format     Abstract available


  56. NAHI H, Genell A, Walinder G, Uttervall K, et al
    Incidence, characteristics and outcome of solitary plasmacytoma and plasma cell leukemia. Population based data from the Swedish Myeloma Register.
    Eur J Haematol. 2017 May 22. doi: 10.1111/ejh.12907.
    PubMed     Text format     Abstract available


  57. KAWAMOTO K, Miyoshi H, Yanagida E, Yoshida N, et al
    Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
    Eur J Haematol. 2017;98:459-466.
    PubMed     Text format     Abstract available


    April 2017
  58. KOZLOWSKI P, Lennmyr E, Ahlberg L, Bernell P, et al
    Age but not Philadelphia positivity impairs outcome in older/elderly patients with acute lymphoblastic leukemia in Sweden.
    Eur J Haematol. 2017 Apr 18. doi: 10.1111/ejh.12896.
    PubMed     Text format     Abstract available


  59. LARFORS G, Sandin F, Richter J, Sjalander A, et al
    The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia.
    Eur J Haematol. 2017;98:398-406.
    PubMed     Text format     Abstract available


  60. RAUTENBERG C, Nachtkamp K, Dienst A, Schmidt PV, et al
    Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT.
    Eur J Haematol. 2017;98:348-354.
    PubMed     Text format     Abstract available


    March 2017
  61. ZADA M, Lerner D, Piltz Y, Perry C, et al
    Familial Chronic Lymphocytic Leukemia in Israel: A Disproportionate Distribution Among Ashkenazi Jews.
    Eur J Haematol. 2017 Mar 31. doi: 10.1111/ejh.12889.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: